Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Plavix Drug Co-marketed by Sanofi SA and Bristol-Myers Squibb to Be Investigated by U.S. Department of Justice-Reuters

Friday, 8 Mar 2013 01:03pm EST 

Reuters reported that Sanofi SA announced that the U.S. Department of Justice (DoJ) is investigating disclosures to the Food & Drug Administration (FDA) about the variable response that certain patients may have to blood-thinner Plavix. Plavix was co-marketed by Sanofi SA and U.S. drugmaker Bristol-Myers Squibb before it lost patent protection in May 2012. The U.S. FDA added a so-called boxed warning to Plavix in 2010 to highlight that the drug could be less effective in certain patients who could not metabolize it properly. The Company announced in its annual report it became aware of the probe in June 2012 and was cooperating with the DoJ. The Company's spokeswoman declined to elaborate on the statement in the annual report. 

Company Quote

0.39 +0.52%
11 Jul 2014